The RATAF II study is a randomized, prospective, parallel group study, designed to compare
the effects of two different drug regimens for rate control in permanent AF (atrial
fibrillation). We will investigate on the difference in effects on exercise capacity,
biomarkers (NT-proBNP (N-terminal pro-brain natriuretic peptide), troponins, hs-CRP), heart
rate, echocardiographic measurements and symptoms.
Our main hypothesis is that six months' treatment with the calcium channel blocker diltiazem
will lower NT-proBNP and increase exercise capacity (peak VO2) compared to treatment with the
beta blocker metoprolol in permanent AF.
Phase:
Phase 4
Details
Lead Sponsor:
Asker & Baerum Hospital
Collaborators:
Helse Sor-Ost Vestre Viken Hospital Trust
Treatments:
Adrenergic beta-1 Receptor Antagonists Diltiazem Metoprolol Molecular Mechanisms of Pharmacological Action Peripheral Nervous System Agents